VANCOUVER, BC – Brains Bioceutical Corp., a global leader in natural, GMP-compliant cannabinoid Active Pharmaceutical Ingredients (APIs), has secured safety approval from the UK’s Food Standards Agency (FSA) and Food Standards Scotland (FSS) for its natural CBD Isolate in food supplements under Novel Foods.
This puts Brains Bio among an elite group of just five companies to advance in the UK’s stringent Novel Food approval process.
Setting Standard for CBD quality, safety
Brains Bio’s ≥98% pure CBD isolate — manufactured at its state-of-the-art GMP facility in Discovery Park, Kent, UK — boasts undetectable THC levels (LOD: 0.000006%) and is backed by over three years of stability data, including Zone IVb. With safety data several multiples over the FSA’s recommended daily dose, the approval cements Brains Bio as a trusted supplier in the evolving CBD market.
Following an in-depth review by the Advisory Committee on Novel Foods and Processes (ACNFP), the FSA and FSS concluded that Brains Bio’s CBD isolate meets the highest safety standards.
“This is a defining moment for Brains Bio and the industry,” said Rick Brar, CEO and chairman of Brains Bio. “Consumers demand purity, consistency, and safety, and this approval validates our commitment to delivering pharmaceutical-grade, natural CBD.”
About Brains Bioceutical Corp.
Brains Bioceutical is a leader in evidence-based and science-led natural plant-based health and wellness solutions. The company manufactures the natural and pure active pharmaceutical ingredients (APIs), with a unique suite of licenses and registrations, The comapny is diversified across the pharmaceutical, medical, and nutraceutical sectors within the rapidly growing cannabinoid market.
